Page last updated: 2024-11-12
tetrakis(acetoxymercuri)methane
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
tetrakis(acetoxymercuri)methane: reagent for labeling sulfur in nucleic acids [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 16683093 |
| SCHEMBL ID | 1310117 |
| MeSH ID | M0066989 |
Synonyms (17)
| Synonym |
|---|
| mercury, tetrakis(acetato)-.mu.4-methanetetrayltetra- |
| nsc-150867 |
| mercury, tetrakis(acetato-o)-.mu.4-methanetetrayltetra- |
| nsc150867 |
| 25201-30-3 |
| SCHEMBL1310117 |
| unii-vcg6x60hjw |
| mercury, tetrakis(acetato)-mu4-methanetetrayltetra- |
| tetrakis(acetoxymercuri)methane |
| vcg6x60hjw , |
| mercury, tetrakis(acetato-o)-mu4-methanetetrayltetra- |
| nsc 150867 |
| DTXSID60179867 |
| mfcd00049094 |
| tetrakis(acetato-.kappa.o)-.mu.4-methanetetrayltetramercury |
| mercury, tetrakis(acetato-.kappa.o)-.mu.4-methanetetrayltetra- |
| acetyloxy-[tris(acetyloxymercurio)methyl]mercury |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.74
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.74) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||